Effect of enteral administration of insulin on intestinal development and feeding tolerance in preterm infants: a pilot study

R J Shulman

Objective: To determine in a pilot study whether enteral administration of insulin to preterm infants (26–29 weeks of gestational age) would enhance gastrointestinal development and reduce feed intolerance without adverse effects.

Design: Eight preterm infants were given 4 U/kg/day insulin enterally from 4 to 28 days of age. Lactase activity was measured at 28 days of age, while measures of feed intolerance were made throughout the hospital stay. The results were compared with those of a matched historical cohort of 80 preterm infants.

Setting: Tertiary care, university affiliated hospital.

Main outcome measures: Lactase activity and feed intolerance.

Results: No adverse effects, such as hypoglycaemia, were observed after administration of insulin. The infants who received insulin had higher lactase activity and less feed intolerance than the controls (30% shorter time to full enteral feeds; fewer gastric residuals per infant).

Conclusions: These preliminary data suggest that enteral insulin administration may be of benefit in reducing feed intolerance in preterm infants. A randomised, blinded trial is warranted.

Materials and methods

Study population

Two groups of infants were compared. Eight insulin treated infants were enrolled during 1997. They were selected sequentially from the Texas Children's Hospital nursery by criteria used in a prospective feeding trial in 1992–1997.6 The infants recruited met the following criteria: 26–30 weeks gestation, determined by a combination of maternal dates and early antenatal ultrasound; gestational age agreement between the two methods of two weeks or less; appropriate size for gestational age; postnatal age < 96 hours; absence of major congenital malformations; and fraction of inspired oxygen < 0.60 at 72 hours.

Matched control infant data were obtained from the prospective feeding trial performed in 1992–1997. Infants from the feeding trial were used as controls in order to obtain comprehensive data on a large number of infants.

Of the 171 infants enrolled in this feeding trial, 80 were found to match the insulin treated infants in terms of gestational age, birth weight, age at which feeds were started, proportion of feeds that were human milk, and feeding method (intermittent bolus every three hours).

The study was approved by the Baylor College of Medicine institutional review board for human subject research. Informed written consent was obtained from parents before enrolment.

Study design

Insulin treated infants received 1 U/kg regular human insulin (Humulin; Eli Lilly & Co, Indianapolis, Indiana, USA) every six hours. The insulin was given through the nasogastric feeding tube, followed by the infant’s usual feed. Insulin administration was begun at 4 days of age and continued to 28 days of age. The dose and duration were based on preliminary studies carried out in newborn pigs.7–9

Feeding began in both groups of infants when they were clinically stable (about 10 days of age). The initial feeding volume was 20 ml/kg/day and the volume was increased by that amount daily until complete enteral feeding was achieved.10 Parenteral nutrition was used until the infants achieved complete enteral feeds, and was adjusted to provide a total intake (enteral and parenteral) of 120 kcal/kg/day.11 The infants received either human milk or Enfamil Premature Formula (Mead-Johnson Nutritional Division, Evansville, Indiana, USA) if the mothers had inadequate milk production. Management of the infants was at the discretion of the attending neonatologists without input from the investigator.
Table 1  Clinical characteristics of preterm infants given insulin or not (controls)

<table>
<thead>
<tr>
<th></th>
<th>Insulin group (n=8)</th>
<th>Control group (n=80)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age (weeks)</td>
<td>27.8 (2.5)</td>
<td>27.8 (1.2)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>973 (310)</td>
<td>1042 (172)</td>
</tr>
<tr>
<td>Age feeds begun (days)</td>
<td>9.9 (4.3)</td>
<td>11.3 (5.2)</td>
</tr>
<tr>
<td>Percentage of feeds with human milk</td>
<td>30 (32)</td>
<td>43 (40)</td>
</tr>
<tr>
<td>Age at lactase measurement (days)</td>
<td>29 (3)</td>
<td>29 (4)</td>
</tr>
<tr>
<td>Antenatal glucocorticoids (n)</td>
<td>4 (50%)</td>
<td>45 (56%)</td>
</tr>
</tbody>
</table>

Values are mean (SD).

Figure 1  Scattergram of lactase activity at 28 days of age in the insulin and control groups (n=6 and 43 respectively; samples could not be obtained from all infants for various reasons, such as the parents and/or attending doctor requesting that the test was not performed or the infants were unstable). The horizontal lines represent the median values. Lactate activity was determined using the urine/milk lactulose/lactose ratio.

Data analysis

Differences between groups were compared using Student’s t-test. Mann-Whitney analysis was used for data not normally distributed. The data are expressed as mean (SD) or median and range as appropriate.

RESULTS

The clinical characteristics of the insulin treated and control infants were well matched (table 1). There was no evidence of hypoglycaemia after the first, second, or fifth dose of insulin (baseline: 8.9 (3.2) mmol/l; 30 min: 9.7 (3.1) mmol/l; 90 min: 9.6 (2.9) mmol/l; mean (SD) for first dose; other data not shown). No untoward effects of the insulin treatment were observed.

At 28 days of age, median lactase activity was higher in the insulin group than in the control group (table 2; fig 1). Lactase measurements were available for six of the eight insulin treated infants and 43 of the controls. The insulin treated infants achieved full enteral feeds earlier and at a younger age than did the controls (table 2).

The insulin treated infants had fewer gastric residuals than the control infants (table 2). This was significant for the number of residuals > 2 ml/kg and borderline significant for residuals that were > 50% of the volume of the previous feed (table 2). There were no differences between groups with respect to the age at discharge (75 (30) days v 81 (33) insulin v control).

DISCUSSION

A large part of the morbidity associated with preterm birth is related to feed intolerance. Given that term infants rarely experience feeding difficulties, it is accepted that feed intolerance in the preterm infant is related to GI immaturity.19 Although various feeding trials and treatments have attempted to ameliorate feed intolerance, they have met with limited success.
In vitro and in vivo work in animals documents the ability of insulin to enhance GI development and function. A growing body of literature from studies in various animal species supports the earlier observation in newborn pigs that administration of enteral insulin also accelerates GI development. Insulin is attractive as an agent to enhance GI development in the preterm infant. It is normally present in human milk at high concentrations relative to maternal blood. It is not absorbed systemically to any significant degree as measured by changes in blood sugar in this study and in a previous investigation. It is inexpensive and readily available.

The results of this study suggest that enteral administration of insulin to preterm infants enhances GI function, as measured by increased lactase activity (table 2, fig 1). Previous studies have documented the importance of lactase activity and lactose digestibility in reducing feed intolerance in preterm infants. This is one possible explanation for the finding that the insulin treated infants achieved full enteral feeds earlier than the control infants and experienced less feed intolerance, as indicated by their lower incidence of increased gastric residuals. The explanation for the outliers in lactase activity in both groups (fig 1) is not clear. The outlier in the insulin group was re-measured at 40 days of age and the value was even higher, suggesting that the value at 28 days of age was not an error. Presumably, this variation in lactase activity in both groups reflects the variability in intestinal maturation among infants. It may explain, in part, why different infants follow such diverse clinical courses.

A limitation of this preliminary study is the retrospective nature of the control infants. However, management of the insulin treated and control infants was similar as it was controlled by nursery protocol. Further, the investigator had no input into the management of any infants as this was in the hands of the various attending neonatologists. Recent studies have documented the value of similar case-controlled investigations.

The goal of this study was to ascertain whether there was evidence that insulin is efficacious in enhancing GI development and reducing feed intolerance in preterm infants. Given that these pilot data support this hypothesis, I suggest that a randomised, placebo controlled trial is indicated. Although I believe the pilot data support this hypothesis, I suggest that a randomised, placebo controlled trial is indicated. Although I believe the pilot data support this hypothesis, I suggest that a randomised, placebo controlled trial is indicated. Although I believe the pilot data support this hypothesis, I suggest that a randomised, placebo controlled trial is indicated. Although I believe the pilot data support this hypothesis, I suggest that a randomised, placebo controlled trial is indicated. Although I believe the pilot data support this hypothesis, I suggest that a randomised, placebo controlled trial is indicated.